Negative impactCompany
Alkem PAT down at ₹675 crore; biotech sales down 37% on ‘lumpy’ CDMO business
BusinessLine 23 min ago·13 Nov 2026, 3:17 am
Alkem reported a revenue increase of roughly 14% to about ₹4,550 crore for the quarter, but its profit after tax fell to ₹675 crore. The drop in earnings was driven largely by a sharp 37% decline in biotech sales, which the company attributed to a ‘lumpy’ contract‑development‑and‑manufacturing‑organisation (CDMO) business that saw uneven order flow.
For investors, the mixed picture highlights a core strength in top‑line growth while exposing vulnerability in higher‑margin biotech operations. The slowdown in CDMO activity can pressure margins, especially if the segment remains volatile, and may affect the company’s ability to convert revenue gains into profit.
Going forward, market participants will be watching Alkem’s order pipeline for the CDMO segment, any cost‑control measures it announces, and the guidance it provides for the next quarter to gauge whether the profit dip is a short‑term blip or a longer‑term trend.
Excerpt from BusinessLine
The company posted total revenue from operations at ₹4,552 crore, up 13.8% compared to the same period last year Alkem Laboratories saw a drop in its consolidated net profit of close to 12 per cent at ₹675 crore, for the second quarter ended September 30, 2026. The company posted total revenue from operations at…Read the original at BusinessLine
Key takeaways
- Category: Company.
- AI reads the tone as negative (potentially bearish) for the stock.
- Assessed as a significant, market-relevant update.
Why it matters
A meaningful update worth tracking. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.
